## Russell C Dale

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3590314/publications.pdf

Version: 2024-02-01

65 papers 8,634 citations

126708 33 h-index 62 g-index

65 all docs

65 does citations

65 times ranked

8423 citing authors

#	Article	IF	CITATIONS
1	A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 391-404.	4.9	2,782
2	International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Multiple Sclerosis Journal, 2013, 19, 1261-1267.	1.4	883
3	Characterization of human disease phenotypes associated with mutations in <i>TREX1</i> , <i>RNASEH2A</i> , <i>RNASEH2B</i> , <i>RNASEH2C</i> , <i>SAMHD1</i> , <i>ADAR</i> , and <i>IFIH1</i> , American Journal of Medical Genetics, Part A, 2015, 167, 296-312.	0.7	447
4	Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 127-137.	0.9	422
5	Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Annals of Neurology, 2009, 66, 833-842.	2.8	283
6	Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology, 2014, 83, 142-150.	1.5	275
7	Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmunity Reviews, 2016, 15, 307-324.	2.5	229
8	Maternal immune activation and neuroinflammation in human neurodevelopmental disorders. Nature Reviews Neurology, 2021, 17, 564-579.	4.9	222
9	CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: A systematic review. Cytokine, 2016, 77, 227-237.	1.4	209
10	Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e40.	3.1	192
11	The Immune System, Cytokines, and Biomarkers in Autism Spectrum Disorder. Neuroscience Bulletin, 2017, 33, 194-204.	1.5	182
12	Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	178
13	Immune therapy in autoimmune encephalitis: a systematic review. Expert Review of Neurotherapeutics, 2015, 15, 1391-1419.	1.4	168
14	Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e12.	3.1	158
15	Maternal acute and chronic inflammation in pregnancy is associated with common neurodevelopmental disorders: a systematic review. Translational Psychiatry, 2021, 11, 71.	2.4	158
16	Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmuneâ€associated epilepsy: Conceptual definitions. Epilepsia, 2020, 61, 1341-1351.	2.6	138
17	Infectious and Autoantibody-Associated Encephalitis: Clinical Features and Long-term Outcome. Pediatrics, 2015, 135, e974-e984.	1.0	115
18	Clinical Characteristics and Functional Motor Outcomes of Enterovirus 71 Neurological Disease in Children. JAMA Neurology, 2016, 73, 300.	4.5	106

#	Article	IF	Citations
19	Utility of CSF Cytokine/Chemokines as Markers of Active Intrathecal Inflammation: Comparison of Demyelinating, Anti-NMDAR and Enteroviral Encephalitis. PLoS ONE, 2016, 11, e0161656.	1.1	102
20	Cerebrospinal fluid neopterin in paediatric neurology: a marker of active central nervous system inflammation. Developmental Medicine and Child Neurology, 2009, 51, 317-323.	1.1	85
21	Rapid Onset Functional Ticâ€Like Behaviors in Young Females During the <scp>COVID</scp> â€19 Pandemic. Movement Disorders, 2021, 36, 2707-2713.	2.2	85
22	Etiology is the key determinant of neuroinflammation in epilepsy: Elevation of cerebrospinal fluid cytokines and chemokines in febrile infectionâ€related epilepsy syndrome and febrile status epilepticus. Epilepsia, 2019, 60, 1678-1688.	2.6	81
23	Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges. Current Opinion in Neurology, 2017, 30, 334-344.	1.8	80
24	Autoimmune epilepsy in children: Case series and proposed guidelines for identification. Epilepsia, 2013, 54, 1036-1045.	2.6	76
25	Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. Acta Neuropathologica Communications, 2019, 7, 145.	2.4	71
26	Genetic, Phenotypic, and Interferon Biomarker Status in ADAR1-Related Neurological Disease. Neuropediatrics, 2017, 48, 166-184.	0.3	62
27	Symptomatic treatment of children with antiâ€NMDAR encephalitis. Developmental Medicine and Child Neurology, 2016, 58, 376-384.	1.1	60
28	An open-label trial of JAK 1/2 blockade in progressive <code><i>IFIH1</i> -associated</code> neuroinflammation. Neurology, 2018, 90, 289-291.	1.5	60
29	Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	58
30	Postencephalitic epilepsy and drugâ€resistant epilepsy after infectious and antibodyâ€associated encephalitis in childhood: Clinical and etiologic risk factors. Epilepsia, 2016, 57, e7-e11.	2.6	54
31	Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibodyâ€associated demyelination in children. Developmental Medicine and Child Neurology, 2019, 61, 610-614.	1.1	51
32	High sensitivity and specificity in proposed clinical diagnostic criteria for antiâ€ <i>N</i> à€methylâ€ <scp>D</scp> â€aspartate receptor encephalitis. Developmental Medicine and Child Neurology, 2017, 59, 1256-1260.	1.1	46
33	Glutamate receptor Î'2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome. Neurology, 2018, 91, e714-e723.	1.5	43
34	Maternal immune conditions are increased in males with autism spectrum disorders and are associated with behavioural and emotional but not cognitive co-morbidity. Translational Psychiatry, 2020, 10, 286.	2.4	40
35	Rapid onset functional ticâ€like behaviours in children and adolescents during <scp>COVID</scp> â€19: Clinical features, assessment and biopsychosocial treatment approach. Journal of Paediatrics and Child Health, 2022, 58, 1181-1187.	0.4	37
36	Association of Maternal Autoimmune Disease With Attention-Deficit/Hyperactivity Disorder in Children. JAMA Pediatrics, 2021, 175, e205487.	3.3	34

#	Article	IF	Citations
37	Maternal autoimmunity and inflammation are associated with childhood tics and obsessive-compulsive disorder: Transcriptomic data show common enriched innate immune pathways. Brain, Behavior, and Immunity, 2021, 94, 308-317.	2.0	32
38	Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and longâ€ŧerm outcome. Developmental Medicine and Child Neurology, 2016, 58, 1180-1192.	1,1	30
39	Cerebrospinal fluid metabolomics: detection of neuroinflammation in human central nervous system disease. Clinical and Translational Immunology, 2021, 10, e1318.	1.7	30
40	Autoantibody-Associated Movement Disorders. Neuropediatrics, 2013, 44, 336-345.	0.3	28
41	Principles and approaches to the treatment of immune-mediated movement disorders. European Journal of Paediatric Neurology, 2018, 22, 292-300.	0.7	24
42	Seizure outcome after corpus callosotomy in a large paediatric series. Developmental Medicine and Child Neurology, 2018, 60, 199-206.	1.1	23
43	Magnetic resonance imaging in enterovirusâ€71, myelin oligodendrocyte glycoprotein antibody, aquaporinâ€4 antibody, and multiple sclerosisâ€associated myelitis in children. Developmental Medicine and Child Neurology, 2019, 61, 1108-1116.	1.1	22
44	Cerebrospinal fluid cytoâ€/chemokine profile during acute herpes simplex virus induced antiâ€ <i>N</i> àâ€methylâ€ <scp>d</scp> â€aspartate receptor encephalitis and in chronic neurological sequelae. Developmental Medicine and Child Neurology, 2017, 59, 806-814.	1.1	20
45	Mycophenolate mofetil, azathioprine and methotrexate usage in paediatric anti-NMDAR encephalitis: A systematic literature review. European Journal of Paediatric Neurology, 2019, 23, 7-18.	0.7	17
46	Mycophenolate mofetil in paediatric autoimmune or immuneâ€mediated diseases of the central nervous system: clinical experience and recommendations. Developmental Medicine and Child Neurology, 2019, 61, 458-468.	1.1	15
47	Maternal immune-related conditions during pregnancy may be a risk factor for neuropsychiatric problems in offspring throughout childhood and adolescence. Psychological Medicine, 2021, 51, 2904-2914.	2.7	15
48	Cerebrospinal fluid metabolites in tryptophanâ€kynurenine and nitric oxide pathways: biomarkers for acute neuroinflammation. Developmental Medicine and Child Neurology, 2021, 63, 552-559.	1.1	15
49	Maternal thyroid autoimmunity associated with acuteâ€onset neuropsychiatric disorders and global regression in offspring. Developmental Medicine and Child Neurology, 2019, 61, 984-988.	1.1	12
50	Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi–GoutiÔres syndrome. Developmental Medicine and Child Neurology, 2022, 64, 266-271.	1.1	12
51	Emerging evidence of Toll-like receptors as a putative pathway linking maternal inflammation and neurodevelopmental disorders in human offspring: A systematic review. Brain, Behavior, and Immunity, 2022, 99, 91-105.	2.0	11
52	Development of a translational inflammation panel for the quantification of cerebrospinal fluid Pterin, Tryptophan-Kynurenine and Nitric oxide pathway metabolites. EBioMedicine, 2022, 77, 103917.	2.7	11
53	Cerebrospinal fluid Bâ€cell expansion in longitudinally extensive transverse myelitis associated with neuromyelitis optica immunoglobulin G. Developmental Medicine and Child Neurology, 2011, 53, 856-860.	1.1	9
54	Effects of the Positive Threshold and Data Analysis on Human MOG Antibody Detection by Live Flow Cytometry. Frontiers in Immunology, 2020, 11, 119.	2,2	7

#	Article	IF	CITATIONS
55	Delivering paediatric precision medicine: Genomic and environmental considerations along the causal pathway of childhood neurodevelopmental disorders. Developmental Medicine and Child Neurology, 2022, 64, 1077-1084.	1.1	7
56	Immunotherapeutics in Pediatric Autoimmune Central Nervous System Disease: Agents and Mechanisms. Seminars in Pediatric Neurology, 2017, 24, 214-228.	1.0	5
57	Psychiatric comorbidity is common in dystonia and other movement disorders. Archives of Disease in Childhood, 2021, 106, 62-67.	1.0	4
58	Opsoclonusâ€myoclonus in Aicardiâ€Goutià res syndrome. Developmental Medicine and Child Neurology, 2021, 63, 1483-1486.	1.1	4
59	Acute encephalopathy with biphasic seizures and restricted diffusion. Journal of Paediatrics and Child Health, 2022, 58, 1688-1690.	0.4	4
60	Autosomal dominant ADAR c.3019G>A (p.(G1007R)) variant is an important mimic of hereditary spastic paraplegia and cerebral palsy. Brain and Development, 2022, 44, 153-160.	0.6	3
61	Treatment Choices in Optic Neuritis: Corticosteroids, Intravenous Immunoglobulin, Plasma Exchange, or Other?. Neuropediatrics, 2016, 47, 137-138.	0.3	1
62	Therapeutic plasma exchange in paediatric neuroimmunology: some evidence but more is needed. Developmental Medicine and Child Neurology, 2019, 61, 504-505.	1.1	1
63	Autoimmune Movement Disorders in Children: Clinical Characteristics and Therapeutic Considerations. Journal of Pediatric Neurology, 2015, 13, 144-154.	0.0	O
64	505Maternal autoimmune disease and increased attention deficit/hyperactivity disorder among offspring: A cohort study and meta-analysis. International Journal of Epidemiology, 2021, 50, .	0.9	0
65	Cerebrospinal fluid free light chain quantitation is a specific biomarker for inflammatory neurological disorders in a paediatric patient cohort. Pathology, 2021, 53, 753-758.	0.3	O